L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer

Pathology International

Volumn 59, Issue 1, 2009, Pages 7-18

  Sakata, Takeshi ^a,b   Ferdous, Golam ^a,b   Tsuruta, Tomoko ^a   Satoh, Takefumi ^a   Baba, Shiro ^a   Muto, Tomoko ^c   Ueno, Akinori ^b   Kanai, Yoshikatsu ^d   Endou, Hitoshi ^b,c   Okayasu, Isao ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Fuji Biomedix ^*  (Japan)

^c KYORIN UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Amino acid transporter; Biomarker; Gleason score; High grade malignancy; Immunohistochemistry; L type amino acid transporter 1; Monoclonal antibody; Prognosis; Prostate cancer

Indexed keywords

AMINO ACID TRANSPORTER; KI 67 ANTIGEN; PROTEIN LAT1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

AGED; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 57649185073     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2008.02319.x     Document Type: Article

References (36)

1. Vickers AJ, Ulmert D, Serio AM et al. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy. Int J Cancer 2007 121 : 2212 17.
2. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998 280 : 969 74.
3. National Comprehensive Cancer Network. Prostate cancer in NCCN Clinical Practice Guidelines. Oncology 2008 1 : 1 44.
4. Namiki M, Ueno S, Kitagawa Y et al. Hormonal therapy. Int J Clin Oncol 2007 12 : 427 32.
5. Kupelian PA, Potters L, Khuntia D et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004 58 : 25 33.
6. Potters L, Morgenstern C, Calugaru E et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005 173 : 1562 6.
7. van Tol-Geerdink JJ, Leer JW, van Lin EN et al. Offering a treatment choice in the irradiation of prostate cancer leads to better informed and more active patients, without harm to well-being. Int J Radiat Oncol Biol Phys 2008 70 : 442 8.
8. Barrqawi AB, Crawford ED. The current use and future trends of focal surgical therapy in the management of localized prostate cancer. Cancer J 2007 13 : 313 17.
9. Kanai Y, Segawa H, Miyamoto K et al. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998 273 : 23 629 32.
10. Kanai Y, Endou H. Heterodimeric amino acid transporters: Molecular biology and pathological and pharmacological relevance. Curr Drug Metab 2001 2 : 339 54.
11. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime? Semin Cancer Biol 2005 15 : 254 66.
12. Kim Do K, Ahn SG, Park JC et al. Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in oral squamous cell carcinoma and its precursor lesion. Anticancer Res 2004 24 : 1671 5.
13. Kobayashi H, Ishii Y, Takayama T. Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol 2005 90 : 233 8.
14. Nii T, Segawa H, Taketani Y et al. Molecular events involved in up-regulating human Na+-independent neutral amino acid transporter LAT1 during T-cell activation. Biochemistry 2001 358 : 693 704.
15. Pineda M, Fernandez E, Torrents D et al. Identification of a membrane protein, LAT-2, that co-expresses with 4F2 heavy chain, an L-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids. J Biol Chem 1999 274 : 19 738 44.
16. Rossier G, Meier C, Bauch C et al. LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of kidney and intestine. J Biol Chem 1999 274 : 34 948 54.
17. Sawasaki T, Ogasawara T, Morishita R, Endo Y. A cell-free protein synthesis system for high-throughput proteomics. Proc Natl Acad Sci USA 2002 99 : 14 652 7.
18. De Masi F, Chiarella P, Wilhelm H et al. High throughput production of mouse monoclonal antibodies using antigen microarrays. Proteomics 2005 5 : 4070 81.
19. Fleming ID, Cooper JS, Henson ED et al., eds. AJCC Cancer Staging Handbook, 5th edn. Philadelphia, PA : Lippincott-Raven, 1997.
20. Satoh T, Yang G, Egawa S et al. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 2003 97 : 1225 33.
21. Epstein JI, Allsbrook WC Jr., Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005 29 : 1228 42.
22. Mikami T, Yoshida T, Akino F et al. Apoptosis regulation differs between ulcerative colitis-associated and sporadic colonic tumors: Association with survivin and Bcl-2. Am J Clin Pathol 2003 119 : 723 30.
23. Takahashi M. Color Atlas of Cancer Cytology, 3rd edn. Tokyo : Igaku-shoin, 2000.
24. Sinicrope FA, Ruan SB, Cleary KR et al. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995 55 : 237 41.
25. Mastroberardino L, Spindler B, Pfeiffer R et al. Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 1998 395 : 288 91.
26. Kim do K, Kanai Y, Matsuo H et al. The human T-type amino acid transporter-1: Characterization, gene organization, and chromosomal location. Genomics 2002 79 : 95 103.
27. Yanagida O, Kanai Y, Chairoungdua A et al. Human L-type amino acid transporter 1 (LAT1): Characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001 1514 : 291 302.
28. Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y. CATs and HATs: The SLC7 family of amino acid transporters. Pflugers Arch 2004 447 : 532 42.
29. Nawashiro H, Otani N, Shinomiya N et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 2006 119 : 484 92.
30. Nakanishi K, Ogata S, Matsuo H et al. Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the urinary tract. Virchows Arch 2007 451 : 681 90.
31. Kaira K, Oriuchi N, Imai H et al. Prognostic significance of L-type amino acid transporter 1 expression in respectable stage I-III nonsmall cell lung cancer. Br J Cancer 2008 98 : 742 8.
32. Nakanishi K, Matsuo H, Kanai Y et al. LAT1 expression in normal lung and in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Virchows Arch 2006 448 : 142 50.
33. Kim CH, Park KJ, Park JR et al. The RNA interference of amino acid transporter LAT1 inhibits the growth of KB human oral cancer cells. Anticancer Res 2006 26 : 2943 8.
34. Karakiewicz PI, Hutterer GC. Predictive models and prostate cancer. Nat Clin Pract Urol 2008 5 : 82 92.
35. Babu E, Kanai Y, Chairoungdua A et al. Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J Biol Chem 2003 44 : 43 838 45.
36. Cole KA, Chuaqui RF, Katz K et al. cDNA sequencing and analysis of POV1 (PB39): A novel gene up-regulated in prostate cancer. Genomics 1998 51 : 282 7.